ArticleInternational urology and nephrology2026
Randomized controlled trial comparing deep dermal glanular hyaluronic acid injection versus oral dapoxetine in management of premature ejaculation.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPremature ejaculation (PE) is a common male sexual dysfunction with significant psychosocial consequences. Available treatment options include behavioral therapy, topical agents, and pharmacological interventions. This randomized controlled trial aims to compare the efficacy and safety of deep dermal glanular hyaluronic acid (HA) injection versus oral dapoxetine in men with lifelong PE refractory to behavioral therapy.
resultsSixty men aged ≥ 18 years were randomly assigned to receive either oral dapoxetine 60 mg three times weekly (Group A) or HA injection into the glans penis (Group B). The primary endpoint was the change in intravaginal ejaculation latency time (IELT) at 6 months following treatment initiation, while secondary outcomes included International Index of Erectile Function-5 (IIEF-5), Index of Premature Ejaculation (IPE), quality of life (QoL), patient satisfaction, and adverse events. Assessments were conducted at baseline and at 1, 3, and 6 months. Both groups demonstrated significant improvements in IELT, IIEF-5, IPE, and QoL at all follow-up time points compared with baseline (p < 0.05). However, improvements were significantly greater in the HA group at 1, 3, and 6 months (p < 0.05). Patient satisfaction was consistently higher in the HA group throughout follow-up (p < 0.05). Adverse events in the dapoxetine group included nausea, dizziness, headache, and dry mouth, whereas the HA group experienced transient injection-site pain, ecchymosis, and bullae formation.
conclusionDeep dermal glanular hyaluronic acid injection is more effective than oral dapoxetine in improving ejaculatory control, sexual function, and quality of life in men with lifelong PE, with an acceptable safety profile.
Indexed as
Identifiers
42477272What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.